<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id><journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id><journal-id journal-id-type="pmc">nar</journal-id><journal-id journal-id-type="publisher-id">Nucleic Acids Research</journal-id><journal-title-group><journal-title>Nucleic Acids Research</journal-title></journal-title-group><issn pub-type="ppub">0305-1048</issn><issn pub-type="epub">1362-4962</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17344318</article-id><article-id pub-id-type="pmc">PMC1874623</article-id><article-id pub-id-type="doi">10.1093/nar/gkm095</article-id><article-categories><subj-group subj-group-type="heading"><subject>Molecular Biology</subject></subj-group></article-categories><title-group><article-title>Role of GAC63 in transcriptional activation mediated by &#x003b2;-catenin</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yong-Heng</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref><xref ref-type="aff" rid="AFF1"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Catherine K.</given-names></name><xref ref-type="aff" rid="AFF1"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Meng</given-names></name><xref ref-type="aff" rid="AFF1"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ou</surname><given-names>Chen-Yin</given-names></name><xref ref-type="aff" rid="AFF1"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Stallcup</surname><given-names>Michael R.</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref><xref ref-type="aff" rid="AFF1"><sup>2</sup></xref><xref ref-type="corresp" rid="COR1">*</xref></contrib></contrib-group><aff id="AFF1"><sup>1</sup>Department of Pathology, <sup>2</sup>Department of Biochemistry and Molecular Biology, and <sup>3</sup>Division of Gastroenterology and Liver Diseases, University of Southern California, Los Angeles, California 90089, USA</aff><author-notes><corresp id="COR1">*To whom correspondence should be addressed. <phone>+1-323 865 3852</phone><fax>+1-323 865 3866</fax><email>stallcup@usc.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2007</year></pub-date><pub-date pub-type="epub"><day>7</day><month>3</month><year>2007</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>3</month><year>2007</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>35</volume><issue>6</issue><fpage>2084</fpage><lpage>2092</lpage><history><date date-type="received"><day>24</day><month>10</month><year>2006</year></date><date date-type="rev-recd"><day>3</day><month>1</month><year>2007</year></date><date date-type="accepted"><day>2</day><month>2</month><year>2007</year></date></history><permissions><copyright-statement>&#x000a9; 2007 The Author(s)</copyright-statement><copyright-year>2007</copyright-year><license license-type="open-access"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/">http://creativecommons.org/licenses/by-nc/2.0/uk/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>&#x003b2;-Catenin is a key mediator in the canonical Wnt signaling pathway, which plays important roles in multiple developmental processes. Inappropriate activation of this pathway leads to developmental defects and development of certain cancers. Upon Wnt signaling, &#x003b2;-catenin binds TCF/LEF transcription factors. The TCF/LEF-&#x003b2;-catenin complex then recruits a variety of transcriptional coactivators to the promoter/enhancer region of Wnt-responsive genes and activates target gene transcription. In this article, we demonstrate that GRIP1-associated coactivator 63 (GAC63), a recently identified nuclear receptor (NR) coactivator, interacts with &#x003b2;-catenin. The N-terminus of GAC63 is the binding site for &#x003b2;-catenin, whereas a C-terminal fragment of &#x003b2;-catenin including armadillo repeats 10&#x02013;12 binds to GAC63. Over-expression of GAC63 enhanced the transcriptional activity of &#x003b2;-catenin, and also greatly enhanced TCF/LEF-regulated reporter gene activity in a &#x003b2;-catenin-dependent manner. Endogenous GAC63 was recruited to TCF/LEF-responsive enhancer elements when &#x003b2;-catenin levels were induced by LiCl. In addition, reduction of endogenous GAC63 level by small interfering RNA (siRNA) inhibited TCF/LEF-mediated gene transcription. Our findings reveal a new function of GAC63 in transcriptional activation of Wnt-responsive genes.</p></abstract></article-meta></front><body><sec><title>INTRODUCTION</title><p>&#x003b2;-Catenin is a key component of the canonical Wnt signaling pathway, which regulates a variety of developmental processes including cell growth and differentiation (<xref ref-type="bibr" rid="B1 B2 B3">1&#x02013;3</xref>). Inappropriate activation of the Wnt signaling pathway is implicated in the development of certain cancers, such as colon cancer (<xref ref-type="bibr" rid="B4 B5 B6 B7">4&#x02013;7</xref>). In the absence of Wnt ligands, cytoplasmic &#x003b2;-catenin levels are kept low through continuous proteasome-mediated degradation, which is controlled by a complex that contains adenomatous polyposis coli (APC), axin and glycogen synthase kinase-3&#x003b2; (GSK-3). These proteins promote the phosphorylation of serine and threonine residues in the NH<sub>2</sub>-terminal region of &#x003b2;-catenin, and target it for degradation by the ubiquitin-dependent proteasome degradation pathway (<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B8">8</xref>). Upon Wnt signaling, the degradation pathway is inhibited, and subsequently &#x003b2;-catenin accumulates in the cytoplasm and nucleus. Nuclear &#x003b2;-catenin binds to transcription factors such as those belonging to the T-cell-specific transcription factor/lymphoid enhancer-binding factor (TCF/LEF) family, and activates the transcription of target genes (<xref ref-type="bibr" rid="B6">6</xref>), such as the genes encoding cyclin D1, c-myc, matrix metalloproteinase-7, neuronal cell adhesion molecule, interleukin-8, FGF20 and DKK1 (<xref ref-type="bibr" rid="B9 B10 B11 B12 B13 B14 B15">9&#x02013;15</xref>), many of which are involved in various developmental and oncogenic processes.</p><p>In the absence of &#x003b2;-catenin binding, TCF/LEF transcription factors repress Wnt target gene transcription by recruiting transcription corepressors such as Groucho/TLE, CtBP and HDAC (<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>). In response to Wnt signaling, &#x003b2;-catenin accumulates, binds to TCF/LEF transcription factors and converts the repressor complex into a transcriptional activator complex by displacement of the corepressors from TCF/LEF and recruitment of additional transcription coactivators. These additional coactivators include histone acetyltransferase p300/CBP (<xref ref-type="bibr" rid="B18 B19 B20 B21">18&#x02013;21</xref>), the SWI/SNF ATPase subunit Brg-1 (<xref ref-type="bibr" rid="B22">22</xref>), p 160 coactivator GRIP1 (<xref ref-type="bibr" rid="B23">23</xref>), histone methyltransferase CARM1(<xref ref-type="bibr" rid="B24">24</xref>), CoCoA (<xref ref-type="bibr" rid="B25">25</xref>), Legless (<xref ref-type="bibr" rid="B26">26</xref>), MED12 (<xref ref-type="bibr" rid="B27">27</xref>), Parafibromin/Hyrax (<xref ref-type="bibr" rid="B28">28</xref>), TRRAP/TIP60, ISW1, MLL/Set1 (<xref ref-type="bibr" rid="B29">29</xref>) and the LIM protein FHL2 (<xref ref-type="bibr" rid="B30">30</xref>). Each transcription coactivator contributes to a signal transduction pathway which transmits the activating signal from the DNA-bound transcriptional activator protein to specific downstream targets in the transcription machinery. For example, a member of the SWI/SNF complex, Brg-1, participates in the remodeling of chromatin conformation around the promoter by means of an ATPase activity (<xref ref-type="bibr" rid="B22">22</xref>). Here, we report the identification of GRIP1-associated coactivator, GAC63, as a novel coactivator for &#x003b2;-catenin.</p><p>GAC63, also known as HUEL, has recently been identified as a nuclear receptor (NR) coactivator (<xref ref-type="bibr" rid="B31">31</xref>). GAC63 interacts with the bHLH-PAS domain of p160 coactivators as well as the ligand-binding domain of some NRs, such as estrogen receptor (ER) and androgen receptor (AR). Over-expression of GAC63 enhanced transcriptional activation by NRs in a hormone-dependent manner. Although GAC63 can interact with NR directly, its coactivator function depends on the presence of a p160 coactivator with an intact N-terminal bHLH-PAS domain. Thus, it functions as a secondary coactivator in NR-mediated gene transcription. A link between GAC63 and &#x003b2;-catenin was first suggested by the findings that both GAC63 and &#x003b2;-catenin interact with androgen receptor (AR) and enhance AR function in an androgen-dependent manner (<xref ref-type="bibr" rid="B31 B32 B33 B34">31&#x02013;34</xref>). Furthermore, a variety of NR coactivators, such as CBP/p300, Brg-1, p160 coactivators, CARM1 and CoCoA, also function as coactivators in TCF/LEF-dependent gene transcription (<xref ref-type="bibr" rid="B18 B19 B20 B21 B22 B23 B24 B25">18&#x02013;25</xref>). Because of these connections, we decided to test whether GAC63 also acts as a coactivator in TCF/LEF-mediated gene transcription.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Plasmids</title><p>The following plasmids were described previously: pSG5. HA-&#x003b2;-catenin, pSG5.HA-LEF1, pGEX-4T1-&#x003b2;-catenin, luciferase reporter plasmid pGL3OT, GK1-LUC (<xref ref-type="bibr" rid="B25">25</xref>); pSG5.HA-GAC63, pSG5.HA-GAC63 (1&#x02013;200), pSG5. HA-GAC63 (200&#x02013;370), pSG5.HA-GAC63 (370&#x02013;567), pGEX-5X1-GAC63 (<xref ref-type="bibr" rid="B31">31</xref>). cDNA fragments encoding the indicated &#x003b2;-catenin amino acids were amplified by PCR and inserted into XhoI and BglII sites of pSG5.HA vector as follows: &#x003b2;-catenin (1&#x02013;140), &#x003b2;-catenin (140&#x02013;664), &#x003b2;-catenin (520&#x02013;781), &#x003b2;-catenin (665&#x02013;781).</p></sec><sec><title>GST pull-down assay</title><p><sup>35</sup>S-labeled full-length GAC63 and its fragments, and &#x003b2;-catenin and its fragments were synthesized <italic>in vitro</italic> by using TNT-Quick coupled transcription/translation system (Promega) according to the manufacturer's protocol. GST pull-down assays were performed as described previously (<xref ref-type="bibr" rid="B31">31</xref>). The amount of GST used as a control was always greater than or equal to the amount of GST fusion protein used.</p></sec><sec><title>Coimmunoprecipitation and immunoblotting</title><p>COS-7 cells were transfected with 3&#x02009;&#x000b5;g pSG5.HA-&#x003b2;-catenin plasmid. Cell lysates were cleared with protein A/G beads (Santa Cruz Biotechnology) for 1&#x02009;h at 4&#x000b0;C. Two micrograms of rabbit anti-GAC63 antibody (<xref ref-type="bibr" rid="B31">31</xref>) or normal rabbit IgG (Santa Cruz Biotechnology) was added to the cell lysates and incubated overnight at 4&#x000b0;C on a rotator. Thirty microliters of protein A/G beads was added and incubated for another 3&#x02009;h. Beads were washed three times with RIPA buffer and subjected to SDS-PAGE. Blots were probed with anti-&#x003b2;-catenin antibody (Santa Cruz Biotechnology).</p><sec><title>Transient transfection assay</title><p>Transient transfection assays were performed with CV-1 cells in 12-well plates as described previously (<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B31">31</xref>). The amount of DNA transfected was held constant in all cases by using the appropriate amount of the empty vector pSG5.HA. Forty-eight hours after transfection, cells were harvested for luciferase activity assays. The results shown are the means and standard deviations of triplicate points and are representative of at least three independent experiments.</p></sec></sec><sec><title>Chromatin immunoprecipitation (ChIP) assays</title><p>ChIP assays were performed with RKO cells treated with or without 50&#x02009;mM LiCl for 45&#x02009;min as described previously (<xref ref-type="bibr" rid="B31">31</xref>), using 2&#x02009;&#x000b5;g of anti-&#x003b2;-catenin antibody (Santa Cruz Biotechnology), 2&#x02009;&#x000b5;g of anti-GAC63 antibody 1bg (<xref ref-type="bibr" rid="B31">31</xref>) or 2&#x02009;&#x000b5;g of normal rabbit IgG (Santa Cruz Biotechnology). Immunoprecipitated, purified, chromosomal DNA was used for PCR amplification, using the following primers: <italic>cyclin D1</italic>: +128 to +486, 5&#x02032;-CGGGGCAGCAGAAGCGAGA-3&#x02032; (forward) and 5&#x02032;-GTGAGTAGCAAAGAAACGTGG-3&#x02032; (reverse); &#x02212;3892 to &#x02212;3649, 5&#x02032;-GGTCCTCCCCGCAGTCTTC-3&#x02032; (forward) and 5&#x02032;-CTCTCCCCCGCAGTCAGG-3&#x02032; (reverse); human <italic>FGF20</italic> promoter, forward 5&#x02032;-CTTTCATGTGTGTCTGGGCAGGTC-3&#x02032; and reverse 5&#x02032;-CTTAAACCGGTCTCCTCTCAAC-3&#x02032;; human <italic>DKK1</italic> promoter, forward 5&#x02032;-GGCCACTTTGATCTCACGCGTC-3&#x02032; and reverse 5&#x02032;-CTGGGAACTTGGGTGCCCTTGCC-3&#x02032;. Quantitative real-time PCR reactions (QPCRs) were performed with 2&#x02009;&#x000b5;l (from a total of 50&#x02009;&#x000b5;l) of immunoprecipitated chromosomal DNA with a Stratagene Mx3000P Instrument, using the same primers as for standard PCR.</p></sec><sec><title>RNA interference</title><p>RNA interference experiments were performed as described previously (<xref ref-type="bibr" rid="B31">31</xref>) using Lipofectamine 2000 (Invitrogen). Small interfering RNA (siRNA) oligonucleotides for GAC63 and scrambled siRNA were synthesized by the USC Norris Comprehensive Cancer Center Microchemical Core Laboratory, and annealed to form duplexes. The following siRNA sequences were used: si-GAC63#1, 5&#x02032;-GCUCUUGCCAGAGAGAAAAdTdT-3&#x02032; (sense) and 5&#x02032;-UUUUCUCUCUGGCAAGAGCdTdT-3&#x02032; (antisense); si-GAC63#2, 5&#x02032;-GAACCUCUCCAAGUAAGAGdTdT-3&#x02032; (sense) and 5&#x02032;-CUCUUACUUGGAGAGGUUCdTdT-3&#x02032; (antisense); si-control with scrambled sequence (negative control siRNA having no perfect matches to known human genes), 5&#x02032;-UUCUCCGAACGUGUCACAUdTdT-3&#x02032; (sense) and 5&#x02032;-AUGUGACACGUUCGGAGAAdTdT-3&#x02032; (antisense). Three days after siRNA transfection, total SW480 cell RNA was extracted with Trizol reagent (Invitrogen), and subjected to reverse transcription (RT) by using iScript cDNA Synthesis Kit (Bio-Rad). Two microliters of RT product was subjected to QPCR analysis. The primers used were as follows: human GAC63, 5&#x02032;-GGCACCTTATTAGGCATGGT-3&#x02032; (forward), 5&#x02032;-GAATTGCCCTTACTGATGGG-3&#x02032; (reverse); human cyclin D1, 5&#x02032;-GCG CCC TCG GTG TCC TAC TTC AAA-3&#x02032; (forward), 5&#x02032;-TCG GGC CGG ATG GAG TTG TCG-3&#x02032; (reverse); human &#x003b2;-actin, 5<bold>&#x02032;</bold>-ACCCCATCGAGCACGGCATCG-3&#x02032; (forward), 5&#x02032;-GTCACCGGAGTCCATCACGATG-3&#x02032; (reverse).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Interaction of GAC63 with &#x003b2;-catenin</title><p>Both &#x003b2;-catenin and GAC63 bind to AR and enhance transcriptional activation by AR (<xref ref-type="bibr" rid="B31 B32 B33 B34">31&#x02013;34</xref>). We therefore tested whether GAC63 can interact with &#x003b2;-catenin <italic>in vitro</italic> using GST pull-down assays. GAC63 synthesized <italic>in vitro</italic> specifically and efficiently bound to GST-&#x003b2;-catenin, while GST alone was unable to pull down GAC63 (<xref ref-type="fig" rid="F1">Figure 1</xref>A). These data suggest that GAC63 binds &#x003b2;-catenin directly <italic>in vitro</italic>.
<fig id="F1" position="float"><label>Figure 1.</label><caption><p>GAC63 interacts with &#x003b2;-catenin <italic>in vitro</italic> and <italic>in vivo</italic>. (<bold>A</bold>) In GST pull-down assays, GST-&#x003b2;-catenin fusion protein was bound to beads and incubated with <italic>in vitro</italic> synthesized and <sup>35</sup>S-labeled GAC63. Bound proteins were eluted and analyzed by SDS-PAGE and autoradiography. (<bold>B</bold>) COS-7 cells were transfected with 3&#x02009;&#x000b5;g pSG5. HA-&#x003b2;-catenin plasmid. The cell extracts were immunoprecipitated with anti-GAC63 antibody or normal rabbit IgG. The immunoprecipitated proteins were detected by immunoblot with anti-&#x003b2;-catenin antibody. (<bold>C</bold>) &#x003b2;-catenin and GAC63 were translated <italic>in vitro</italic> and tested for binding to GST or GST-LEF1.</p></caption><graphic xlink:href="gkm095f1"/></fig></p><p>To test for binding in vivo, we performed coimmunoprecipitation assay. COS-7 cells were transiently transfected with &#x003b2;-catenin, and cell lysates were immunoprecipitated by anti-GAC63 antibody followed by immunoblotting analysis with anti-&#x003b2;-catenin antibody. &#x003b2;-catenin was coimmunoprecipitated by antibody against GAC63, but not by normal rabbit IgG (<xref ref-type="fig" rid="F1">Figure 1</xref>B). Thus, these results indicate that GAC63 interacts with &#x003b2;-catenin <italic>in vivo</italic>.</p><p>We also tested whether GAC63 binds to LEF1 in GST pull-down assays. &#x003b2;-catenin synthesized <italic>in vitro</italic> bound strongly and specifically to GST-LEF1 (<xref ref-type="fig" rid="F1">Figure 1</xref>C, upper panel), but GAC63 synthesized <italic>in vitro</italic> did not (<xref ref-type="fig" rid="F1">Figure 1</xref>C, lower panel). These results suggest that GAC63 cannot interact directly with LEF1 <italic>in vitro</italic>.</p></sec><sec><title>Mapping of interaction domains in GAC63 and &#x003b2;-catenin</title><p>GAC63 has a zinc-finger-like motif at the N-terminus, two leucine-zipper-like motifs at the central region and an LXXLL motif and an acidic region at the C-terminus (<xref ref-type="bibr" rid="B35">35</xref>) (<xref ref-type="fig" rid="F2">Figure 2</xref>A). To narrow down the &#x003b2;-catenin interaction domain in GAC63, a series of GAC63 deletion mutants were synthesized <italic>in vitro</italic>, and tested for their binding to GST-&#x003b2;-catenin. Among them, a fragment of the N-terminal region (amino acids 1&#x02013;200) efficiently and specifically bound GST-&#x003b2;-catenin, but fragments of the central region (amino acids 200&#x02013;370) and the C-terminus (amino acids 370&#x02013;567) bound weakly or not at all (<xref ref-type="fig" rid="F2">Figure 2</xref>B). Taken together, these results suggest that &#x003b2;-catenin directly binds to the N-terminus of GAC63.
<fig id="F2" position="float"><label>Figure 2.</label><caption><p>Determination of interaction domains of GAC63 and &#x003b2;-catenin. (<bold>A</bold>) Functional domains of GAC63 and &#x003b2;-catenin. Numbers beneath each diagram indicate amino acids. LXXLL, leucine-rich motif; LZ, leucine zipper-like motif. Numbered segments of &#x003b2;-catenin represent armadillo repeats. (<bold>B</bold>) The indicated GAC63 fragments were synthesized <italic>in vitro</italic> and tested in GST pull-down assays for binding to GST or GST-&#x003b2;-catenin. (<bold>C</bold>) The <italic>in vitro</italic> synthesized &#x003b2;-catenin fragments were tested in GST pull-down assays for binding to GST or GST-GAC63.</p></caption><graphic xlink:href="gkm095f2"/></fig></p><p>&#x003b2;-catenin is composed of three domains: a regulatory N-terminal region followed by 12 armadillo (Arm) repeats and a C-terminal transactivation domain (<xref ref-type="bibr" rid="B36">36</xref>) (<xref ref-type="fig" rid="F2">Figure 2</xref>A). In order to determine the domain of &#x003b2;-catenin that interacts with GAC63, we performed GST pull-down assays using a series of &#x003b2;-catenin deletion mutants. GST-GAC63 specifically bound a &#x003b2;-catenin fragment consisting of Arm repeats 10&#x02013;12 and the C-terminal activation domain. No interaction was seen with the N-terminus, Arm repeats 1&#x02013;12 or the C-terminus alone (<xref ref-type="fig" rid="F2">Figure 2</xref>C). These results suggest that a C-terminal fragment of &#x003b2;-catenin consisting of Arm repeats 10&#x02013;12 and the C-terminal activation domain binds GAC63.</p></sec><sec><title>GAC63 functions as a &#x003b2;-catenin dependent
coactivator in TCF/LEF-mediated transcription</title><p>GAC63 is a secondary coactivator in NR-mediated gene transcription. Although it can bind NR directly as well as the p160 NR coactivator GRIP1, its coactivator function depends on the presence of GRIP1 (<xref ref-type="bibr" rid="B31">31</xref>). On the other hand, &#x003b2;-catenin can bind directly to TCF/LEF proteins and activate TCF/LEF-mediated gene transcription (<xref ref-type="bibr" rid="B6">6</xref>). Since GAC63 interacts with &#x003b2;-catenin, we tested whether GAC63 also functions as a coactivator in the TCF/LEF-mediated pathway in transient transfection assays using the luciferase reporter plasmid pGL3OT, which contains TCF/LEF-responsive elements. As expected, &#x003b2;-catenin enhanced the reporter gene activity by 6-fold (<xref ref-type="fig" rid="F3">Figure 3</xref>A, assay 4). Over-expression of GAC63 alone had little effect on reporter gene activity (<xref ref-type="fig" rid="F3">Figure 3</xref>A, assays 2 and 3). However, over-expression of GAC63 and &#x003b2;-catenin together dramatically and synergistically increased reporter gene expression up to 60-fold (<xref ref-type="fig" rid="F3">Figure 3</xref>A, assays 5 and 6). The over-expression of GAC63 had no effect on the level of &#x003b2;-catenin expressed (data not shown). In another control experiment, the mutant reporter plasmid pGL3OF, containing mutant TCF/LEF-responsive elements, was not activated by either &#x003b2;-catenin alone or &#x003b2;-catenin plus GAC63 (data not shown). These results, along with the inability of GAC63 to bind directly to LEF1, suggest that GAC63 functions as a secondary coactivator in TCF/LEF-mediated transcriptional activation, i.e. the coactivator function of GAC63 depends on the presence of &#x003b2;-catenin.
<fig id="F3" position="float"><label>Figure 3.</label><caption><p>GAC63 functions as a &#x003b2;-catenin dependent coactivator in TCF/LEF-mediated transcription. (<bold>A</bold>) CV-1 cells were transfected in 12-well plates with 200&#x02009;ng pGL3OT reporter plasmid; 10&#x02009;ng pSG5.HA-LEF1; 100&#x02009;ng pSG5.HA-&#x003b2;-catenin; and 200&#x02009;ng (+) or 400&#x02009;ng (++) pSG5.HA-GAC63 as indicated. Results shown are representative of three independent experiments. (<bold>B</bold>) CV-1 cells were transfected with 200&#x02009;ng of GK1-LUC reporter plasmid, 200&#x02009;ng of plasmid encoding Gal4 DBD or Gal4-LEF1, either 400&#x02009;ng of GAC63 expression plasmid, or 200&#x02009;ng of &#x003b2;-catenin, or both. The luciferase activity results shown are representative of three independent experiments. (<bold>C</bold>) CV-1 cells were transfected with 200&#x02009;ng of GK1-LUC reporter plasmid, 200&#x02009;ng of plasmid encoding Gal4 DBD or Gal4-&#x003b2;-catenin, and 400&#x02009;ng of GAC63 expression plasmid as indicated. The luciferase activity results shown are representative of three independent experiments.</p></caption><graphic xlink:href="gkm095f3"/></fig></p><p>To further evaluate this hypothesis, we tested the effect of GAC63 on the transcriptional activity of LEF1 fused to the Gal4 DNA-binding domain (DBD), in the absence or presence of &#x003b2;-catenin. Gal4DBD-LEF1 fusion protein itself only had a weak autonomous transactivation activity to activate transcription of a reporter gene containing Gal4 response elements, and &#x003b2;-catenin strongly enhanced this activity (<xref ref-type="fig" rid="F3">Figure 3</xref>B, assays 5 and 6). In the absence of &#x003b2;-catenin, GAC63 had little effect on the Gal4-responsive reporter gene expression (<xref ref-type="fig" rid="F3">Figure 3</xref>B, assay 7); however, in the presence of &#x003b2;-catenin, GAC63 acted synergistically with &#x003b2;-catenin to enhance the reporter gene expression (<xref ref-type="fig" rid="F3">Figure 3</xref>B, assay 8). These data further support the idea that GAC63 enhances LEF1 activity through &#x003b2;-catenin.</p><p>Since GAC63 enhances LEF1 transcriptional activity through &#x003b2;-catenin, we then tested whether GAC63 could affect the transcriptional activity of &#x003b2;-catenin. In transiently transfected CV1 cells, Gal4DBD-&#x003b2;-catenin fusion protein showed modest autonomous transactivation activity to activate transcription of the Gal4-responsive reporter gene (<xref ref-type="fig" rid="F3">Figure 3</xref>C, assay 3). This activity was further enhanced (up to 7-fold) by co-expression of GAC63 (<xref ref-type="fig" rid="F3">Figure 3</xref>C, assay 4). Thus, GAC63 enhances the transcriptional activity of &#x003b2;-catenin.</p></sec><sec><title>Endogenous GAC63 is recruited to TCF/LEF-responsive enhancer elements upon LiCl treatment</title><p>To test whether endogenous GAC63 is specifically recruited to endogenous TCF/LEF-responsive enhancer elements <italic>in vivo</italic>, we employed chromatin immunoprecipitation (ChIP) assays to examine the <italic>cyclin D1</italic> promoter in RKO colon cancer cells upon the addition of LiCl, a GSK-3&#x003b2; inhibitor. To determine the optimal concentration of LiCl to inhibit the degradation of &#x003b2;-catenin, RKO cells were treated with different concentrations of LiCl for 45&#x02009;min. As shown in <xref ref-type="fig" rid="F4">Figure 4</xref>A, &#x003b2;-catenin protein levels increased upon the addition of LiCl in a dose-dependent manner. Thus, we decided to treat RKO cells with 50&#x02009;mM LiCl for 45&#x02009;min in ChIP assays. As expected, &#x003b2;-catenin was recruited to <italic>cyclin D1</italic> promoter region after a 45-min LiCl treatment. Similarly, endogenous GAC63 was also recruited to this promoter upon the addition of LiCl (<xref ref-type="fig" rid="F4">Figure 4</xref>B). Normal IgG served as a negative control, and the input chromatin levels from LiCl-treated or untreated cells were equivalent. The recruitment of &#x003b2;-catenin and GAC63 was specific for the promoter region of <italic>cyclin D1</italic> gene, because PCRs with primers for a region 3.6&#x02009;kb upstream which lacked TCF/LEF-binding sites failed to produce a signal from the same immunoprecipitated chromatin fraction. QPCR analysis confirmed the recruitment of &#x003b2;-catenin and GAC63 to the promoter region of <italic>cyclin D1</italic> upon LiCl treatment (<xref ref-type="fig" rid="F4">Figure 4</xref>C). The same immunoprecipitated chromatin fraction was also tested by PCR using primers to amplify the promoter regions of two other Wnt target genes, <italic>FGF20</italic> and <italic>DKK1</italic> (<xref ref-type="bibr" rid="B15">15</xref>). Both &#x003b2;-catenin and GAC63 were recruited to these promoter regions upon LiCl treatment (<xref ref-type="fig" rid="F4">Figure 4</xref>D).
<fig id="F4" position="float"><label>Figure 4.</label><caption><p>Endogenous GAC63 is recruited to TCF/LEF-responsive <italic>cyclin D1</italic> promoter region upon LiCl treatment. (<bold>A</bold>) RKO cells were treated with different concentrations of LiCl for 45&#x02009;min. Cell extracts were tested by immunoblotting using anti-&#x003b2;-catenin antibody. (<bold>B</bold>) RKO cells were grown with or without 50&#x02009;mM LiCl for 45&#x02009;min and analyzed by chromain immunoprecipitation assays, using the indicated antibodies for immunoprecipitation. The immunoprecipitated DNA was amplified by PCR using primers to amplify the promoter region of <italic>cyclin D1</italic> gene and a region 3.6&#x02009;kb upstream. Results shown are representative of two independent experiments. (<bold>C</bold>) QPCR analysis of immunoprecipitated RKO cell chromosomal DNA using primers for the TCF/LEF binding region of <italic>cyclin D1</italic> gene was performed with 2&#x02009;&#x000b5;l samples. The results are shown as percentage of input, are the mean and S.D. from triplicate reactions, and are representative of two independent experiments. (<bold>D</bold>) PCR analysis of immunoprecipitated RKO cell chromosomal DNA using primers for the promoter regions of <italic>FGF20</italic> and <italic>DKK1</italic> genes. Results shown are representative of two independent experiments.</p></caption><graphic xlink:href="gkm095f4"/></fig></p></sec><sec><title>Endogenous GAC63 is important for efficient
transcriptional activation by LEF1</title><p>Over-expression of GAC63 enhances LEF1-responsive reporter gene expression (<xref ref-type="fig" rid="F3">Figure 3</xref>A). To test for a physiological role of endogenous GAC63 in the process of transcriptional activation by LEF1, we examined the effect of reduced endogenous GAC63 on LEF1-regulated <italic>cyclin D1</italic> gene expression in SW480 colon cancer cells. These cells contain a mutation in the adenomatous polyposis coli protein, which regulates &#x003b2;-catenin degradation. Thus, these cells have elevated levels of wild-type &#x003b2;-catenin, and therefore they have elevated expression of <italic>cyclin D1</italic> mRNA and protein (<xref ref-type="bibr" rid="B25">25</xref>). Two different siRNAs targeting the human GAC63 sequence specifically reduced the level of endogenous GAC63 mRNA (<xref ref-type="fig" rid="F5">Figure 5</xref>A, upper panel) and protein (<xref ref-type="fig" rid="F5">Figure 5</xref>B, upper panel), while the non-specific control siRNA did not. The expression of the LEF1- and &#x003b2;-catenin-regulated <italic>cyclin D1</italic> gene was inhibited by 40&#x02013;50% in the presence of siRNA against GAC63, but was not affected by an equivalent amount of control siRNA with scrambled sequence (<xref ref-type="fig" rid="F5">Figure 5</xref>A, lower panel). The effect on <italic>cyclin D1</italic> gene expression was specific, since the results shown are normalized to the level of &#x003b2;-actin transcripts. Thus, although many different coactivators are involved in mediating transcriptional activation by LEF1 and &#x003b2;-catenin, endogenous GAC63 is important for efficient induction of the LEF1- and &#x003b2;-catenin-regulated <italic>cyclin D1</italic> gene.
<fig id="F5" position="float"><label>Figure 5.</label><caption><p>Endogenous GAC63 is important for efficient transcriptional activation by LEF1. (<bold>A</bold>) SW480 cells were transfected with siRNA duplex against GAC63 or a non-specific control siRNA duplex. After 72&#x02009;h, cells were harvested for either immunoblots or total RNA preparation. mRNA was analyzed by RT-QPCR to measure the levels of human GAC63, cyclin D1 and &#x003b2;-actin transcripts. Results shown for GAC63 and cyclin D1 transcripts were normalized by the levels of &#x003b2;-actin transcripts and are representative of three independent experiments. A paired, two-tailed <italic>t</italic>-test performed on the values from the three experiments indicated that the siRNA against GAC63 caused significant decreases in the expression levels of cyclin D1 mRNA (<italic>P</italic> = 0.0004 for 1 and <italic>P</italic> = 0.0008 for #2). For the three experiments, the mean decrease and 95% confidence intervals were 85 &#x000b1; 5% (#1) and 85 &#x000b1; 7% (#2) for GAC63 mRNA, and 46 &#x000b1; 12% (#1) and 51 &#x000b1; 7% (#2) for cyclin D1 mRNA. (<bold>B</bold>) Cell extracts were also tested by immunoblotting using anti-GAC63 and anti-actin antibodies.</p></caption><graphic xlink:href="gkm095f5"/></fig></p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The Wnt signaling pathway plays important roles in multiple developmental processes and cancer (<xref ref-type="bibr" rid="B1 B2 B3 B4 B5 B6 B7">1&#x02013;7</xref>). Upon Wnt signaling, &#x003b2;-catenin associates with TCF/LEF transcription factors and recruits a variety of transcriptional coactivators to the promoter/enhancer regions of Wnt-responsive genes. Here we report that GAC63 is a novel binding partner and coactivator of &#x003b2;-catenin. GAC63 binds &#x003b2;-catenin <italic>in vitro</italic> and <italic>in vivo</italic>, but does not bind directly to LEF1 (<xref ref-type="fig" rid="F1">Figure 1</xref>). Over-expression of GAC63 enhanced TCF/LEF-mediated transcription in a &#x003b2;-catenin-dependent manner (<xref ref-type="fig" rid="F3">Figure 3</xref>). Taken together, our data suggest that GAC63 functions as a secondary coactivator in TCF/LEF-mediated transcriptional activation, that is, its coactivator function depends on the presence of &#x003b2;-catenin. Moreover, upon LiCl treatment, endogenous GAC63 is recruited to the promoter regions of endogenous Wnt target genes, such as <italic>cyclin D1, FGF20</italic> and <italic>DKK1</italic> (<xref ref-type="fig" rid="F4">Figure 4</xref>). In addition, reduction of endogenous GAC63 by siRNA inhibited the TCF/LEF- and &#x003b2;-catenin-mediated expression of the <italic>cyclin D1</italic> gene by 40&#x02013;50% in a cell line with constitutively high levels of &#x003b2;-catenin and cyclin D1 expression (<xref ref-type="fig" rid="F5">Figure 5</xref>). The lack of complete inhibition by siRNA could be due to residual GAC63, or the compensatory effects by other transcription coactivators, such as CBP/p300, Brg-1, GRIP1, CARM1 and CoCoA, which also bind to &#x003b2;-catenin and serve as secondary coactivators for TCF/LEF transcription factors. Furthermore, GAC63 could be recruited to other regulatory sites on the <italic>cyclin D1</italic> promoter in addition to the TCF/LEF-binding site; therefore, it is possible that the reduced cyclin D1 expression observed when GAC63 levels are reduced by siRNA could be due to reduced GAC63 interactions at the TCF/LEF site and other regulatory sites. While we do not know whether GAC63 is required for &#x003b2;-catenin-mediated up-regulation of cyclin D1 expression in all regulatory settings, our data as a whole make a compelling case that GAC63 plays an important role in &#x003b2;-catenin- and TCF/LEF-mediated transcription. We therefore conclude that GAC63 is a physiological component of TCF/LEF- and &#x003b2;-catenin-mediated transactivation, and is important for optimal transcriptional activation mediated by &#x003b2;-catenin and TCF/LEF in at least some cases.</p><p>In previous studies, GAC63 has been shown to function as a secondary coactivator for NRs by cooperating with p160 coactivators (<xref ref-type="bibr" rid="B31">31</xref>). The current study shows that GAC63 functions as a secondary coactivator for another class of transcription factor, TCF/LEF, by cooperating with &#x003b2;-catenin. GAC63 also works as a primary coactivator for the aryl hydrocarbon receptor (AHR), i.e. it binds directly to AHR (<xref ref-type="bibr" rid="B37">37</xref>). Thus, GAC63 functions as a general transcriptional coactivator for multiple signaling pathways. However, we cannot rule out the possibility that GAC63 could also act as corepressor in certain conditions. A number of proteins have been shown to act as either coactivator or corepressor in a promoter-specific manner. For example, members of the p160 coactivators, such as GRIP1, function as glucocorticoid receptor (GR) coactivators. However, at the promoters of certain GR target genes that are repressed by hormone-activated GR, such as the human collagenase-3 gene and osteocalcin gene, GRIP1 acts as a GR corepressor (<xref ref-type="bibr" rid="B38">38</xref>).</p><p>GAC63 functions as a coactivator in multiple signaling pathways; however, the mechanisms by which GAC63 contributes to transcriptional activation are yet to be established. GAC63 has an N-terminal region containing a zinc-finger-like motif, a central domain containing two leucine-zipper-like motifs, and a C-terminal region with a LXXLL motif and an acidic region (<xref ref-type="bibr" rid="B35">35</xref>). One region of the GAC63 protein (amino acids 127&#x02013;196) was shown to have sequence similarity (34%) to the DNA-binding domain (amino acids 21&#x02013;95) of the XPA DNA repair protein (SWISS-PROT accession no. Q64029) (<xref ref-type="bibr" rid="B39">39</xref>). Another GAC63 region (amino acids 239&#x02013;533) shares homology with members of the zinc transporter family. In fragment studies, the N-terminus and central region of GAC63 both bind GRIP1, while only the N-terminus binds &#x003b2;-catenin. When fused to Gal4 DNA-binding domain, the C-terminus of GAC63 showed weak autonomous transcriptional activation activity (<xref ref-type="bibr" rid="B31">31</xref>). GAC63 also contains several nuclear localization signals and a nuclear-export-like signal; the human ortholog of GAC63, HUEL, has been shown to undergo nuclear translocation during S phase (<xref ref-type="bibr" rid="B39">39</xref>).</p><p>&#x003b2;-Catenin has been shown to be a coactivator for TCF/LEF transcription factors as well as androgen receptor. This provides a mechanism for crosstalk between the Wnt and AR signaling pathways. In addition, these two pathways share a number of transcriptional coactivators, such as CBP/p300 (<xref ref-type="bibr" rid="B18 B19 B20 B21">18&#x02013;21</xref>), Brg-1 (<xref ref-type="bibr" rid="B22">22</xref>), p160 coactivators (<xref ref-type="bibr" rid="B23">23</xref>), CARM1 (<xref ref-type="bibr" rid="B24">24</xref>) and CoCoA (<xref ref-type="bibr" rid="B25">25</xref>). GAC63 provides yet another example of a transcriptional coactivator that is involved in both signaling pathways. Furthermore, members of the NR superfamily, such as androgen receptor (AR), thyroid hormone receptor (TR) and retinoic acid receptor (RAR), have been shown to interfere with the Wnt signaling pathway (<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B40 B41 B42 B43 B44 B45">40&#x02013;45</xref>). The antagonistic effect by AR could be due to the competition for common transcriptional coactivators, in addition to other proposed mechanisms, such as increased degradation of &#x003b2;-catenin (<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B46">46</xref>).</p><p>In our study, GAC63 bound to a &#x003b2;-catenin fragment consisting of Arm repeats 10&#x02013;12 and the C-terminal activation domain. Several other proteins have been reported to bind to a similar &#x003b2;-catenin subdomain, and contribute to transcriptional activation. These proteins include CBP/p300, MED12, Parafibromin/Hyrax, TRRAP/TIP60, ISW1 and MLL/Set1 (<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B27 B28 B29">27&#x02013;29</xref>,<xref ref-type="bibr" rid="B47">47</xref>). It remains to be determined whether these coactivators can bind to &#x003b2;-catenin at the same time and function synergistically as coactivators, or whether some of them may compete for binding and inhibit each other's function or play different roles on various promoters. For example, although CBP and p300 are closely related, they play opposite roles on the expression of some &#x003b2;-catenin target genes, such as survivin (<xref ref-type="bibr" rid="B48">48</xref>). The small molecule ICG-001, which blocks the CBP&#x02013;&#x003b2;-catenin interaction but not the p300&#x02013;&#x003b2;-catenin interaction, inhibits survivin gene expression. In the absence of ICG-001, CBP is recruited to the survivin promoter, and promotes survivin gene expression; however, in the presence of ICG-001, there is less CBP on the survivin promoter but more p300 instead, which leads to concomitant recruitment of repressive elements and results in transcription repression.</p><p>Inappropriate activation of the Wnt signaling pathway occurs in many types of cancer, and is caused by mutations of many of the Wnt signaling components (<xref ref-type="bibr" rid="B4 B5 B6 B7">4&#x02013;7</xref>). The two genes found most frequently mutated are adenomatous polyposis coli (APC) and &#x003b2;-catenin. These mutations generally lead to stabilization of &#x003b2;-catenin, and an over-activation of the Wnt signaling pathway. This over-activation is thought in part to promote oncogenesis through over-expression of Wnt-responsive genes, such as <italic>c-myc</italic> and <italic>cyclin D1</italic> (<xref ref-type="bibr" rid="B9 B10 B11">9&#x02013;11</xref>). Since GAC63 cooperates with &#x003b2;-catenin to activate Wnt-responsive gene expression, GAC63 might play a role in the oncogenic processes. Furthermore, in DNA microarray studies, GAC63 (C4orf1) over-expression has been shown to be associated with lymph node metastasis of breast cancer (<xref ref-type="bibr" rid="B49">49</xref>). In addition, a distinct alternative transcript encoding GAC63 with a modified and truncated C-terminus was detected in the HT-1080 fibrosarcoma, G-401 Wilms tumor and SiHa cervical carcinoma cell lines (<xref ref-type="bibr" rid="B35">35</xref>). These findings indicate that GAC63 might be involved in the development of cancer. The role of GAC63 in oncogenesis, and the mechanisms by which GAC63 contributes to oncogenesis are currently under investigation in our laboratory.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>We thank Daniel Gerke and Kelly Chang (University of Southern California) for expert technical assistance. This work was supported by grant DK43093 to M.R.S. from the U.S. National Institutes of Health. Y.H.C. was supported in part by a predoctoral fellowship from the University of Southern California/Norris Breast Cancer Research Training Program. Funding to pay the Open Access publication charge was provided by grant DK43093 to M.R.S. from the United States National Institutes of Health and by the University of Southern California.</p><p><italic>Conflict of interest statement</italic>. None declared.</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Brown</surname><given-names>JD</given-names></name><name><surname>Torres</surname><given-names>M</given-names></name></person-group><article-title>WNTs modulate cell fate and behavior during vertebrate development</article-title><source>Trends Genet</source><year>1997</year><volume>13</volume><fpage>157</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">9097727</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JR</given-names></name><name><surname>Hocking</surname><given-names>AM</given-names></name><name><surname>Brown</surname><given-names>JD</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name></person-group><article-title>Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca<sup>2+</sup> pathways</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>7860</fpage><lpage>7872</lpage><pub-id pub-id-type="pmid">10630639</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadigan</surname><given-names>KM</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><article-title>Wnt signaling: a common theme in animal development</article-title><source>Genes Dev</source><year>1997</year><volume>11</volume><fpage>3286</fpage><lpage>3305</lpage><pub-id pub-id-type="pmid">9407023</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polakis</surname><given-names>P</given-names></name></person-group><article-title>Wnt signaling and cancer</article-title><source>Genes Dev</source><year>2000</year><volume>14</volume><fpage>1837</fpage><lpage>1851</lpage><pub-id pub-id-type="pmid">10921899</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reya</surname><given-names>T</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Wnt signalling in stem cells and cancer</article-title><source>Nature</source><year>2005</year><volume>434</volume><fpage>843</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">15829953</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Kohn</surname><given-names>AD</given-names></name><name><surname>Ferrari</surname><given-names>GVD</given-names></name><name><surname>Kaykas</surname><given-names>A</given-names></name></person-group><article-title>Wnt and [beta]-catenin signalling: diseases and therapies</article-title><source>Nat. Rev. Genet</source><year>2004</year><volume>5</volume><fpage>691</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">15372092</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giles</surname><given-names>RH</given-names></name><name><surname>van Es</surname><given-names>JH</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Caught up in a Wnt storm: Wnt signaling in cancer</article-title><source>Biochim. Biophys. Acta Rev. Cancer</source><year>2003</year><volume>1653</volume><fpage>1</fpage><lpage>24</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aberle</surname><given-names>H</given-names></name><name><surname>Bauer</surname><given-names>A</given-names></name><name><surname>Stappert</surname><given-names>J</given-names></name><name><surname>Kispert</surname><given-names>A</given-names></name><name><surname>Kemler</surname><given-names>R</given-names></name></person-group><article-title>beta-Catenin is a target for the ubiquitin-proteasome pathway</article-title><source>EMBO J</source><year>1997</year><volume>16</volume><fpage>3797</fpage><lpage>3804</lpage><pub-id pub-id-type="pmid">9233789</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>TC</given-names></name><name><surname>Sparks</surname><given-names>AB</given-names></name><name><surname>Rago</surname><given-names>C</given-names></name><name><surname>Hermeking</surname><given-names>H</given-names></name><name><surname>Zawel</surname><given-names>L</given-names></name><name><surname>da Costa</surname><given-names>LT</given-names></name><name><surname>Morin</surname><given-names>PJ</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><article-title>Identification of c-MYC as a target of the APC pathway</article-title><source>Science</source><year>1998</year><volume>281</volume><fpage>1509</fpage><lpage>1512</lpage><pub-id pub-id-type="pmid">9727977</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tetsu</surname><given-names>O</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><article-title>[beta]-Catenin regulates expression of cyclin D1 in colon carcinoma cells</article-title><source>Nature</source><year>1999</year><volume>398</volume><fpage>422</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">10201372</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shtutman</surname><given-names>M</given-names></name><name><surname>Zhurinsky</surname><given-names>J</given-names></name><name><surname>Simcha</surname><given-names>I</given-names></name><name><surname>Albanese</surname><given-names>C</given-names></name><name><surname>D'Amico</surname><given-names>M</given-names></name><name><surname>Pestell</surname><given-names>R</given-names></name><name><surname>Ben Ze'ev</surname><given-names>A</given-names></name></person-group><article-title>The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>5522</fpage><lpage>5527</lpage><pub-id pub-id-type="pmid">10318916</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brabletz</surname><given-names>T</given-names></name><name><surname>Jung</surname><given-names>A</given-names></name><name><surname>Dag</surname><given-names>S</given-names></name><name><surname>Hlubek</surname><given-names>F</given-names></name><name><surname>Kirchner</surname><given-names>T</given-names></name></person-group><article-title>{beta}-Catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer</article-title><source>Am. J. Pathol</source><year>1999</year><volume>155</volume><fpage>1033</fpage><lpage>1038</lpage><pub-id pub-id-type="pmid">10514384</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conacci-Sorrell</surname><given-names>ME</given-names></name><name><surname>Ben Yedidia</surname><given-names>T</given-names></name><name><surname>Shtutman</surname><given-names>M</given-names></name><name><surname>Feinstein</surname><given-names>E</given-names></name><name><surname>Einat</surname><given-names>P</given-names></name><name><surname>Ben Ze'ev</surname><given-names>A</given-names></name></person-group><article-title>Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis</article-title><source>Genes Dev</source><year>2002</year><volume>16</volume><fpage>2058</fpage><lpage>2072</lpage><pub-id pub-id-type="pmid">12183361</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>L</given-names></name><name><surname>Neuveut</surname><given-names>C</given-names></name><name><surname>Renard</surname><given-names>CA</given-names></name><name><surname>Charneau</surname><given-names>P</given-names></name><name><surname>Branchereau</surname><given-names>S</given-names></name><name><surname>Gauthier</surname><given-names>F</given-names></name><name><surname>Van Nhieu</surname><given-names>JT</given-names></name><name><surname>Cherqui</surname><given-names>D</given-names></name><name><surname>Petit-Bertron</surname><given-names>AF</given-names></name><etal/></person-group><article-title>Transcriptional activation of interleukin-8 by beta-catenin-Tcf4</article-title><source>J. Biol. Chem</source><year>2002</year><volume>277</volume><fpage>42386</fpage><lpage>42393</lpage><pub-id pub-id-type="pmid">12200448</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamorro</surname><given-names>MN</given-names></name><name><surname>Schwartz</surname><given-names>DR</given-names></name><name><surname>Vonica</surname><given-names>A</given-names></name><name><surname>Brivanlou</surname><given-names>AH</given-names></name><name><surname>Cho</surname><given-names>KR</given-names></name><name><surname>Varmus</surname><given-names>HE</given-names></name></person-group><article-title>FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development</article-title><source>EMBO J</source><year>2005</year><volume>24</volume><fpage>73</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">15592430</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roose</surname><given-names>J</given-names></name><name><surname>Molenaar</surname><given-names>M</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><name><surname>Hurenkamp</surname><given-names>J</given-names></name><name><surname>Brantjes</surname><given-names>H</given-names></name><name><surname>Moerer</surname><given-names>P</given-names></name><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>Destree</surname><given-names>O</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors</article-title><source>Nature</source><year>1998</year><volume>395</volume><fpage>608</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">9783587</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brannon</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>JD</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Kimelman</surname><given-names>D</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name></person-group><article-title>XCtBP is a XTcf-3 co-repressor with roles throughout Xenopus development</article-title><source>Development</source><year>1999</year><volume>126</volume><fpage>3159</fpage><lpage>3170</lpage><pub-id pub-id-type="pmid">10375506</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hecht</surname><given-names>A</given-names></name><name><surname>Vleminckx</surname><given-names>K</given-names></name><name><surname>Stemmler</surname><given-names>MP</given-names></name><name><surname>van Roy</surname><given-names>F</given-names></name><name><surname>Kemler</surname><given-names>R</given-names></name></person-group><article-title>The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates</article-title><source>EMBO J</source><year>2000</year><volume>19</volume><fpage>1839</fpage><lpage>1850</lpage><pub-id pub-id-type="pmid">10775268</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyagishi</surname><given-names>M</given-names></name><name><surname>Fujii</surname><given-names>R</given-names></name><name><surname>Hatta</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>E</given-names></name><name><surname>Araya</surname><given-names>N</given-names></name><name><surname>Nagafuchi</surname><given-names>A</given-names></name><name><surname>Ishihara</surname><given-names>S</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Fukamizu</surname><given-names>A</given-names></name></person-group><article-title>Regulation of Lef-mediated transcription and p53-dependent pathway by associating beta-catenin with CBP/p300</article-title><source>J. Biol. Chem</source><year>2000</year><volume>275</volume><fpage>35170</fpage><lpage>35175</lpage><pub-id pub-id-type="pmid">10906119</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Kolligs</surname><given-names>FT</given-names></name><name><surname>Hottiger</surname><given-names>MO</given-names></name><name><surname>Mosavin</surname><given-names>R</given-names></name><name><surname>Fearon</surname><given-names>ER</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name></person-group><article-title>Regulation of beta-catenin transformation by the p300 transcriptional coactivator</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2000</year><volume>97</volume><fpage>12613</fpage><lpage>12618</lpage><pub-id pub-id-type="pmid">11050151</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takemaru</surname><given-names>KI</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name></person-group><article-title>The transcriptional coactivator CBP interacts with {beta}-catenin to activate gene expression</article-title><source>J. Cell. Biol</source><year>2000</year><volume>149</volume><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">10769018</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>N</given-names></name><name><surname>Hurlstone</surname><given-names>A</given-names></name><name><surname>Musisi</surname><given-names>H</given-names></name><name><surname>Miles</surname><given-names>A</given-names></name><name><surname>Bienz</surname><given-names>M</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation</article-title><source>EMBO J</source><year>2001</year><volume>20</volume><fpage>4935</fpage><lpage>4943</lpage><pub-id pub-id-type="pmid">11532957</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Koh</surname><given-names>SS</given-names></name><name><surname>Stallcup</surname><given-names>MR</given-names></name></person-group><article-title>Synergistic effects of coactivators GRIP1 and {beta}-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways</article-title><source>J. Biol. Chem</source><year>2004</year><volume>279</volume><fpage>4212</fpage><lpage>4220</lpage><pub-id pub-id-type="pmid">14638683</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>SS</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Widelitz</surname><given-names>RB</given-names></name><name><surname>Chuong</surname><given-names>CM</given-names></name><name><surname>Stallcup</surname><given-names>MR</given-names></name></person-group><article-title>Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and beta-catenin with two different classes of DNA-binding transcriptional activators</article-title><source>J. Biol. Chem</source><year>2002</year><volume>277</volume><fpage>26031</fpage><lpage>26035</lpage><pub-id pub-id-type="pmid">11983685</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>CK</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Stallcup</surname><given-names>MR</given-names></name></person-group><article-title>Differential use of functional domains by coiled-coil coactivator in its synergistic coactivator function with beta-catenin or GRIP1</article-title><source>J. Biol. Chem</source><year>2006</year><volume>281</volume><fpage>3389</fpage><lpage>3397</lpage><pub-id pub-id-type="pmid">16344550</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramps</surname><given-names>T</given-names></name><name><surname>Peter</surname><given-names>O</given-names></name><name><surname>Brunner</surname><given-names>E</given-names></name><name><surname>Nellen</surname><given-names>D</given-names></name><name><surname>Froesch</surname><given-names>B</given-names></name><name><surname>Chatterjee</surname><given-names>S</given-names></name><name><surname>Murone</surname><given-names>M</given-names></name><name><surname>Zullig</surname><given-names>S</given-names></name><name><surname>Basler</surname><given-names>K</given-names></name></person-group><article-title>Wnt/Wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex</article-title><source>Cell</source><year>2002</year><volume>109</volume><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">11955446</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Hecht</surname><given-names>A</given-names></name><name><surname>Boyer</surname><given-names>TG</given-names></name></person-group><article-title>Mediator is a transducer of Wnt/beta-catenin signaling</article-title><source>J. Biol. Chem</source><year>2006</year><volume>281</volume><fpage>14066</fpage><lpage>14075</lpage><pub-id pub-id-type="pmid">16565090</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosimann</surname><given-names>C</given-names></name><name><surname>Hausmann</surname><given-names>G</given-names></name><name><surname>Basler</surname><given-names>K</given-names></name></person-group><article-title>Parafibromin/hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/armadillo</article-title><source>Cell</source><year>2006</year><volume>125</volume><fpage>327</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">16630820</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sierra</surname><given-names>J</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Joazeiro</surname><given-names>CA</given-names></name><name><surname>Jones</surname><given-names>KA</given-names></name></person-group><article-title>The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes</article-title><source>Genes Dev</source><year>2006</year><volume>20</volume><fpage>586</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">16510874</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Renard</surname><given-names>CA</given-names></name><name><surname>Labalette</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Levy</surname><given-names>L</given-names></name><name><surname>Neuveut</surname><given-names>C</given-names></name><name><surname>Prieur</surname><given-names>X</given-names></name><name><surname>Flajolet</surname><given-names>M</given-names></name><name><surname>Prigent</surname><given-names>S</given-names></name><etal/></person-group><article-title>Identification of the LIM Protein FHL2 as a Coactivator of beta-catenin</article-title><source>J. Biol. Chem</source><year>2003</year><volume>278</volume><fpage>5188</fpage><lpage>5194</lpage><pub-id pub-id-type="pmid">12466281</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Stallcup</surname><given-names>MR</given-names></name></person-group><article-title>GAC63, a GRIP1-dependent nuclear receptor coactivator</article-title><source>Mol. Cell Biol</source><year>2005</year><volume>25</volume><fpage>5965</fpage><lpage>5972</lpage><pub-id pub-id-type="pmid">15988012</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlowski</surname><given-names>JE</given-names></name><name><surname>Ertel</surname><given-names>JR</given-names></name><name><surname>Allen</surname><given-names>MP</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Butler</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>EM</given-names></name><name><surname>Wierman</surname><given-names>ME</given-names></name></person-group><article-title>Liganded androgen receptor interaction with beta-catenin. nuclear co-localization and modulation of transcriptional activity in neuronal cells</article-title><source>J. Biol. Chem</source><year>2002</year><volume>277</volume><fpage>20702</fpage><lpage>20710</lpage><pub-id pub-id-type="pmid">11916967</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Sasaki</surname><given-names>CY</given-names></name><name><surname>Longo</surname><given-names>DL</given-names></name><name><surname>Lim</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name></person-group><article-title>Linking beta-catenin to androgen-signaling pathway</article-title><source>J. Biol. Chem</source><year>2002</year><volume>277</volume><fpage>11336</fpage><lpage>11344</lpage><pub-id pub-id-type="pmid">11792709</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Truica</surname><given-names>CI</given-names></name><name><surname>Byers</surname><given-names>S</given-names></name><name><surname>Gelmann</surname><given-names>EP</given-names></name></person-group><article-title>{beta}-Catenin affects androgen receptor transcriptional activity and ligand specificity</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>4709</fpage><lpage>4713</lpage><pub-id pub-id-type="pmid">10987273</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>DLC</given-names></name><name><surname>Chow</surname><given-names>VTK</given-names></name></person-group><article-title>The novel human HUEL (C4orf1) gene maps to chromosome 4p12-p13 and encodes a nuclear protein containing the nuclear receptor interaction motif</article-title><source>Genomics</source><year>1999</year><volume>59</volume><fpage>224</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">10409434</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willert</surname><given-names>K</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><article-title>Beta-catenin: a key mediator of Wnt signaling</article-title><source>Curr. Opin. Genet. Dev</source><year>1998</year><volume>8</volume><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">9529612</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Beischlag</surname><given-names>TV</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Perdew</surname><given-names>GH</given-names></name><name><surname>Stallcup</surname><given-names>MR</given-names></name></person-group><article-title>Role of GAC63 in transcriptional activation mediated by the aryl hydrocarbon receptor</article-title><source>J. Biol. Chem</source><year>2006</year><volume>281</volume><fpage>12242</fpage><lpage>12247</lpage><pub-id pub-id-type="pmid">16513642</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogatsky</surname><given-names>I</given-names></name><name><surname>Luecke</surname><given-names>HF</given-names></name><name><surname>Leitman</surname><given-names>DC</given-names></name><name><surname>Yamamoto</surname><given-names>KR</given-names></name></person-group><article-title>Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2002</year><volume>99</volume><fpage>16701</fpage><lpage>16706</lpage><pub-id pub-id-type="pmid">12481024</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>DLC</given-names></name><name><surname>Yeo</surname><given-names>WM</given-names></name><name><surname>Chow</surname><given-names>VTK</given-names></name></person-group><article-title>The novel human HUEL (C4orf1) protein shares homology with the DNA-binding domain of the XPA DNA repair protein and displays nuclear translocation in a cell cycle-dependent manner</article-title><source>Int. J. Biochem. Cell Biol</source><year>2002</year><volume>34</volume><fpage>487</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">11906820</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulholland</surname><given-names>DJ</given-names></name><name><surname>Dedhar</surname><given-names>S</given-names></name><name><surname>Coetzee</surname><given-names>GA</given-names></name><name><surname>Nelson</surname><given-names>CC</given-names></name></person-group><article-title>Interaction of nuclear receptors with the Wnt/{beta}-catenin/Tcf signaling axis: Wnt you like to know?</article-title><source>Endocr. Rev</source><year>2005</year><volume>26</volume><fpage>898</fpage><lpage>915</lpage><pub-id pub-id-type="pmid">16126938</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>LN</given-names></name><name><surname>Herrell</surname><given-names>R</given-names></name><name><surname>Byers</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>EM</given-names></name><name><surname>Gelmann</surname><given-names>EP</given-names></name></person-group><article-title>{beta}-Catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription</article-title><source>Mol. Cell Biol</source><year>2003</year><volume>23</volume><fpage>1674</fpage><lpage>1687</lpage><pub-id pub-id-type="pmid">12588987</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulholland</surname><given-names>DJ</given-names></name><name><surname>Read</surname><given-names>JT</given-names></name><name><surname>Rennie</surname><given-names>PS</given-names></name><name><surname>Cox</surname><given-names>ME</given-names></name><name><surname>Nelson</surname><given-names>CC</given-names></name></person-group><article-title>Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>5602</fpage><lpage>5613</lpage><pub-id pub-id-type="pmid">12944908</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Hecht</surname><given-names>A</given-names></name><name><surname>Pestell</surname><given-names>R</given-names></name><name><surname>Byers</surname><given-names>SW</given-names></name></person-group><article-title>Trans-repression of {beta}-catenin activity by nuclear receptors</article-title><source>J. Biol. Chem</source><year>2003</year><volume>278</volume><fpage>48137</fpage><lpage>48145</lpage><pub-id pub-id-type="pmid">12972427</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Easwaran</surname><given-names>V</given-names></name><name><surname>Pishvaian</surname><given-names>M</given-names></name><name><surname>Salimuddin</surname></name><name><surname>Byers</surname><given-names>S</given-names></name></person-group><article-title>Cross-regulation of [beta]-catenin-LEF/TCF and retinoid signaling pathways</article-title><source>Curr. Biol</source><year>1999</year><volume>9</volume><fpage>1415</fpage><lpage>1419</lpage><pub-id pub-id-type="pmid">10607566</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>LD</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Guo</surname><given-names>QM</given-names></name><name><surname>Alkharouf</surname><given-names>NW</given-names></name><name><surname>Malek</surname><given-names>RL</given-names></name><name><surname>Lee</surname><given-names>NH</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name><name><surname>Cheng</surname><given-names>SY</given-names></name></person-group><article-title>Silencing of Wnt signaling and activation of multiple metabolic pathways in response to thyroid hormone-stimulated cell proliferation</article-title><source>Mol. Cell Biol</source><year>2001</year><volume>21</volume><fpage>6626</fpage><lpage>6639</lpage><pub-id pub-id-type="pmid">11533250</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natsume</surname><given-names>H</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name><name><surname>Kitagawa</surname><given-names>M</given-names></name><name><surname>Kashiwabara</surname><given-names>Y</given-names></name><name><surname>Matsushita</surname><given-names>A</given-names></name><name><surname>Nakano</surname><given-names>K</given-names></name><name><surname>Nishiyama</surname><given-names>K</given-names></name><name><surname>Nagayama</surname><given-names>K</given-names></name><name><surname>Misawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>[beta]-Catenin/Tcf-1-mediated transactivation of cyclin D1 promoter is negatively regulated by thyroid hormone</article-title><source>Biochem. Biophy. Res. Commun</source><year>2003</year><volume>309</volume><fpage>408</fpage><lpage>413</lpage></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadeli</surname><given-names>R</given-names></name><name><surname>Hoffmans</surname><given-names>R</given-names></name><name><surname>Basler</surname><given-names>K</given-names></name></person-group><article-title>Transcription under the control of nuclear Arm/beta-catenin</article-title><source>Curr. Biology</source><year>2006</year><volume>16</volume><fpage>R378</fpage><lpage>R385</lpage></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Nguyen</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Kahn</surname><given-names>M</given-names></name></person-group><article-title>Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>3619</fpage><lpage>3631</lpage><pub-id pub-id-type="pmid">15782138</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Cheng</surname><given-names>SH</given-names></name><name><surname>Dressman</surname><given-names>H</given-names></name><name><surname>Pittman</surname><given-names>J</given-names></name><name><surname>Tsou</surname><given-names>MH</given-names></name><name><surname>Horng</surname><given-names>CF</given-names></name><name><surname>Bild</surname><given-names>A</given-names></name><name><surname>Iversen</surname><given-names>ES</given-names></name><name><surname>Liao</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gene expression predictors of breast cancer outcomes</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>1590</fpage><lpage>1596</lpage><pub-id pub-id-type="pmid">12747878</pub-id></element-citation></ref></ref-list></back></article>
